Cd38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy

HIGHLIGHTS

• who: Luca Julius Pape and colleagues from the Pasteur Institute of Iran, Iran Shanghai Jiao Tong University, China have published the paper: CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy, in the Journal: (JOURNAL)
• what: The authors show that JK36 also detects CD38-expressing tumor cells with greater sensitivity pretreated mice resulted in weaker staining, possibly reflecting downregulation of CD38 due to therapeutic effects of daratumumab and JK36-hcAb in_vivo during the 24 hours of pretreatment and six hours imaging period. The study demonstrates that a nanobody recognizing a distinct . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.